Advancements in the Management of Relapsed/Refractory B-Cell Malignancies – Integrating Recent Data into Practice to Improve Outcomes

Despite advancements in the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and mantle cell lymphoma (MCL), resistance and recurrence occur frequently and mutations might develop during treatment. Given the diverse range of treatment side effects, it is critical that hematology/oncology clinicians know how to select appropriate medications for each patient as well as have insight about optimization of drug sequencing, used alone or in combination, and the issue of intolerance. Clinicians must possess a comprehensive understanding of these challenges and implement specific management of drug-related toxicities using a shared decision-making and multidisciplinary approach.

In this CE Concepts Grand Rounds series, expert faculty will explore the latest clinical trial data on novel treatment options for patients with resistant/recurrent (R/R) CLL/SLL, utilization of an evidence-based approach for personalizing treatment for patients with R/R MCL, and prioritization of patient adherence and active engagement through development of multidisciplinary frameworks to oversee and address adverse events. The faculty will also provide insight through case-based discussions.

At the conclusion of this activity, learners will be able to better:

• Implement novel treatment options for patients with R/R CLL/SLL based on the latest clinical trial data
• Utilize an evidence-based approach for personalizing treatment for patients with R/R MCL
• Develop team-based frameworks to oversee and address adverse events, prioritizing patient adherence and active engagement

This program is supported by an independent educational grant from Lilly.

Academic and community hematologists/oncologists, nurse practitioners (NPs), physician associates (PAs), nurses, and pharmacists

It is the policy of CE Concepts, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CE Concepts, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Allan reports the following financial relationships:

Advisory Board: NeoGenomics Laboratories

Consultant: AbbVie Inc.; Adaptive Biotechnologies; AstraZeneca; BeiGene; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc. (DMSB Chair); and Pharmacyclics

Research Support: BeiGene; Celgene Corporation/Bristol Myers Squibb; Genentech, Inc.; and Janssen Pharmaceuticals, Inc.

Speakers Bureau: AbbVie Inc. and BeiGene

The following individuals have no financial relationships to disclose:

Alaa Bawaneh, MD, PhD (Peer Reviewer)
Albert Eubanks, Jr., RN (Peer Reviewer)
Susan Perry (Planning Committee)
David Modrak, PhD (Planning Committee)
Scott J. Hershman, MD, FACEHP, CHCP (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Sharon Tordoff (Planning Committee)

*All identified conflicts of interest have been mitigated.

Unlabeled Use Disclosure
Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CE Concepts, LLC, the faculty, planners, and reviewers do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.